Can Patients with Clarithromycin-Resistant Helicobacter pylori Infection Be Treated with a 7-Day Bismuth-Based Quadruple Therapy?

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
² Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

Editorial

Jung-Wook Kim et al. Gut Liver. 2024.

. 2024 Nov 15;18(6):931-933.

doi: 10.5009/gnl240511.

¹ Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
² Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

No abstract available

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288. - DOI - PubMed
1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi: 10.1136/gut.2009.192757. - DOI - PubMed
1. Jung HK, Kang SJ, Lee YC, et al. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021;15:168–195. doi: 10.5009/gnl20288.79060f1d36de42079f62692d803f29ef - DOI - PMC - PubMed
1. Chang YW, Shin GY, Kim JW, et al. Cost-effectiveness of empirical bismuth-based quadruple therapy and tailored therapy after clarithromycin resistance tests for Helicobacter pylori eradication. Dig Dis Sci. 2022;67:1222–1230. doi: 10.1007/s10620-021-06938-y. - DOI - PubMed
1. Duan M, Kong Q, Wang H, Li Y. Optimal duration of bismuth-containing quadruple therapy for helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2024;29:e13144. doi: 10.1111/hel.13144. - DOI - PubMed